Compare XNCR & MFIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XNCR | MFIC |
|---|---|---|
| Founded | 1997 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2013 | 2004 |
| Metric | XNCR | MFIC |
|---|---|---|
| Price | $18.36 | $12.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 6 |
| Target Price | ★ $23.20 | $12.96 |
| AVG Volume (30 Days) | ★ 758.3K | 513.7K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 12.42% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.07 |
| Revenue | $150,132,000.00 | ★ $324,678,000.00 |
| Revenue This Year | $22.09 | $10.19 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $11.45 |
| Revenue Growth | ★ 38.16 | 11.35 |
| 52 Week Low | $6.92 | $10.18 |
| 52 Week High | $27.24 | $14.74 |
| Indicator | XNCR | MFIC |
|---|---|---|
| Relative Strength Index (RSI) | 68.18 | 58.51 |
| Support Level | $15.69 | $12.06 |
| Resistance Level | $17.83 | $12.24 |
| Average True Range (ATR) | 1.01 | 0.20 |
| MACD | 0.10 | 0.05 |
| Stochastic Oscillator | 91.72 | 93.33 |
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.